SEC Form 15F-12B filed by Neovasc Inc.

$NVCN
Pharmaceuticals and Biotechnology
Health Care
Get the next $NVCN alert in real time by email
15F-12B 1 tm2313323d1_15f12b.htm 15F-12B

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15F

 

CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION

OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE

ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION

13(a) OR SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-36458

 

NEOVASC INC.

(Exact name of registrant as specified in its charter)

 

Suite 5138 - 13562 Maycrest Way

Richmond, British Columbia, Canada, V6V 2J7

(604) 270-4344

(Address, including zip code, and telephone number, including area code,

of registrant’s principal executive offices)

 

Common Shares, no par value

(Title of each class of securities covered by this Form)

 

Place an X in the appropriate box(es) to indicate the provision(s) relied upon to terminate the duty to file reports under the Securities Exchange Act of 1934:

 

  Rule 12h-6(a) x Rule 12h-6(d) ¨
  (for equity securities)   (for successor registrants)  
         
  Rule 12h-6(c) ¨ Rule 12h-6(i) ¨
  (for debt securities)   (for prior Form 15 filers)  

 

 

 

 

 

PART I

 

Item 1. Exchange Act Reporting History

 

A. Neovasc Inc. (the “Company”) voluntarily applied for Securities and Exchange Commission (the “SEC”) registration pursuant to Section 13(a) and Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on April 17, 2014 with the filing of a Registration Statement on Form F-10. The Registration Statement on Form F-10 was declared effective by the SEC on May 15, 2014, which resulted in the Company’s shares being registered under Section 12(b) of the Exchange Act and a duty to file reports under Section 13(a) or Section 15(d) of the Exchange Act.

 

B. The Company has filed or furnished all reports required under Exchange Act Section 13(a) or Section 15(d) and the corresponding SEC rules for the 12 months preceding the filing of this Form 15F, and has filed at least one annual report under Section 13(a) of the Exchange Act.

 

Item 2. Recent United States Market Activity

 

The Company’s securities were last sold in the United States in a registered offering under the Securities Act of 1933, as amended in February 2021. On April 11, 2023, the Company filed post-effective amendments with the SEC pursuant to Form S-8, Form F-3 and Form-10 to terminate the registration of all unsold securities under such registration statements.

 

Item 3. Foreign Listing and Primary Trading Market

 

A. The Company’s common shares were listed on the Toronto Stock Exchange in Canada. The common shares were delisted from the Toronto Stock Exchange on April 11, 2023. The Toronto Stock Exchange constituted the primary trading market for the Company’s common shares.

 

B. The date of the initial listing of the Company’s common shares on the Toronto Stock Exchange was May 25, 2001. The Company maintained the listing of the common shares on the Toronto Stock Exchange for at least 12 months prior to the filing of this Form 15F.

 

C. During the 12-month period beginning on April 11, 2022 and ended on April 10, 2023, 4.99% of the average daily trading in the Company’s common shares occurred on the Toronto Stock Exchange.

 

Item 4. Comparative Trading Volume Data

 

Not applicable.

 

Item 5. Alternative Record Holder Information

 

As of April 11, 2023, the number of record holders of the Company’s common shares on a worldwide basis was one.

 

Item 6. Debt Securities

 

Not applicable.

 

Item 7. Notice Requirement

 

A. On March 6, 2023 (“March 6 Release”), and again on April 11, 2023 (“April 11 Release”), a press release was published providing notice of the Company's intent to delist the common shares and terminate the Company’s registration of a class of securities and its reporting obligations under Section 13(a) or Section 15(d) of the Exchange Act.

 

 

 

B. The press releases were publicly disseminated by NewsMedia wire for the March 6 Release and Global Newswire for the April 11 Release. Further, each was furnished to the SEC under cover of two Form 6-Ks, filed on March 7, 2023 and on April 11, 2023.

 

Item 8. Prior Form 15 Filers

 

Not applicable.

 

PART II

 

Item 9. Rule 12g3-2(b) Exemption

 

All information required to be published pursuant to Rule 12g3-2(b)(1)(iii) will be available at www.sedar.com.

 

PART III

 

Item 10. Exhibits

 

None.

 

Item 11. Undertakings

 

The undersigned issuer hereby undertakes to withdraw this Form 15F if, at any time before the effectiveness of its termination of reporting under Rule 12h-6, it has actual knowledge of information that causes it reasonably to believe that, at the time of filing the Form 15F:

 

(1)    The average daily trading volume of its subject class of securities in the United States exceeded 5 percent of the average daily trading volume of that class of securities on a worldwide basis for the same recent 12-month period that the issuer used for purposes of Rule 12h-6(a)(4)(i);

 

(2)    Its subject class of securities was held of record by 300 or more United States residents or 300 or more persons worldwide, if proceeding under Rule 12h-6(a)(4)(ii) or Rule 12h-6(c); or

 

(3)    It otherwise did not qualify for termination of its Exchange Act reporting obligations under Rule 12h-6.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Neovasc Inc. has duly authorized the undersigned person to sign on its behalf this certification on Form 15F. In so doing, Neovasc Inc. certifies that, as represented on this Form, it has complied with all of the conditions set forth in Rule 12h-6 for terminating its registration under section 12(g) of the Exchange Act, or its duty to file reports under section 13(a) or section 15(d) of the Exchange Act, or both.

 

Date: April 24, 2023  
   
NEOVASC INC.
  By /s/ Daniel K. Puckett
    Daniel K. Puckett, President  

 

 

Get the next $NVCN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVCN

DatePrice TargetRatingAnalyst
More analyst ratings

$NVCN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Volato Announces Changes to Board Composition

    Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

    $BSX
    $SOAR
    $NVCN
    Medical/Dental Instruments
    Health Care
    Transportation Services
    Consumer Discretionary
  • Neovasc Shareholders Approve Acquisition by Shockwave Medical

    Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
  • Neovasc Shareholders Approve Acquisition by Shockwave Medical

    VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care

$NVCN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NVCN
SEC Filings

See more

$NVCN
Financials

Live finance-specific insights

See more
  • Volato Announces Changes to Board Composition

    Volato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger

    $BSX
    $SOAR
    $NVCN
    Medical/Dental Instruments
    Health Care
    Transportation Services
    Consumer Discretionary
  • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

    VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") ((NASDAQ, TSX:NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company re

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care
  • Neovasc to Report Third Quarter Financial Results on November 10, 2022

    VANCOUVER and MINNEAPOLIS, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022. Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc we

    $NVCN
    Pharmaceuticals and Biotechnology
    Health Care

$NVCN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more